Why the study?
It is crucial to manage accidental or intentional overdose with new oral anticoagulants developed to overcome the monitoring difficulties and narrow therapeutic range of warfarin.
This review summarizes the characteristics of novel oral anticoagulants and the management of their toxicity and overdose.
Extended life expectancy, changes in dietary habits, and a sedentary lifestyle have contributed to an increased risk of stroke and myocardial infarction. Atherosclerosis and thrombosis are the underlying causes of stroke and myocardial infarction. Anticoagulants have a significant role in both the prevention and treatment of these conditions. The difficulty of monitoring warfarin derivatives, which have been in use until recently, and their narrow therapeutic range paved the way for the development and use of new oral anticoagulants. Rivaroxaban, Apixaban, Edoxaban, and Betrixaban are Factor Xa inhibitors, while Dabigatran is a Thrombin (FIIa) inhibitor, and together they comprise the new oral anticoagulants. It is crucial to manage any accidental or intentional overdose with these new oral anticoagulants. The present review focuses on the characteristics of novel anticoagulants and their toxicological management.
No takes yet. Share an insight, caveat, or question.
Çelik et al. (2024) conducted a review in New oral anticoagulant toxicity. New oral anticoagulants and specific antidotes was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: